Shaanxi Kanghui Pharm Co Ltd Cash Flow Conversion Efficiency
Shaanxi Kanghui Pharm Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Shaanxi Kanghui Pharm Co Ltd (603139) has a cash flow conversion efficiency ratio of 0.010x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥7.14 Million ≈ $1.04 Million USD) by net assets (CN¥745.41 Million ≈ $109.08 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Shaanxi Kanghui Pharm Co Ltd (2012–2025)
Cash flow conversion efficiency of Shaanxi Kanghui Pharm Co Ltd from 2012 to 2025. This chart illustrates how Shaanxi Kanghui Pharm Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Shaanxi Kanghui Pharm Co Ltd share price for real-time trading data and today's change.
Shaanxi Kanghui Pharm Co Ltd Cash Flow Conversion Ratio Explained
Shaanxi Kanghui Pharm Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Shaanxi Kanghui Pharm Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shaanxi Kanghui Pharm Co Ltd ranked by their cash flow conversion efficiency. Also see 603139 stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Quanta Storage
TWO:6188
|
0.205x |
|
Caleres Inc
NYSE:CAL
|
-0.045x |
|
Shanghai Welltech Automation Co Ltd
SHE:002058
|
0.072x |
|
Shandong Donghong Pipe Ind Co
SHG:603856
|
0.021x |
|
Nanjing Zhongbei Group Co Ltd
SHE:000421
|
0.037x |
|
Excelsior Medical Co Ltd
TW:4104
|
-0.022x |
|
Epigral Ltd.
NSE:EPIGRAL
|
0.120x |
|
Guangzhou Hangxin Aviation Technology Co Ltd
SHE:300424
|
0.071x |
Annual Cash Flow Conversion Efficiency for Shaanxi Kanghui Pharm Co Ltd (2012–2025)
The table below shows the annual cash flow conversion efficiency of Shaanxi Kanghui Pharm Co Ltd from 2012 to 2025. Review Shaanxi Kanghui Pharm Co Ltd (603139) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥568.98 Million ≈ $83.26 Million |
CN¥-16.72 Million ≈ $-2.45 Million |
-0.029x | -171.46% |
| 2024-12-31 | CN¥906.90 Million ≈ $132.71 Million |
CN¥37.29 Million ≈ $5.46 Million |
0.041x | +158.14% |
| 2023-12-31 | CN¥1.02 Billion ≈ $149.25 Million |
CN¥-72.13 Million ≈ $-10.56 Million |
-0.071x | -243.87% |
| 2022-12-31 | CN¥1.03 Billion ≈ $150.13 Million |
CN¥50.43 Million ≈ $7.38 Million |
0.049x | +638.84% |
| 2021-12-31 | CN¥1.12 Billion ≈ $163.16 Million |
CN¥7.42 Million ≈ $1.09 Million |
0.007x | -92.38% |
| 2020-12-31 | CN¥1.07 Billion ≈ $157.00 Million |
CN¥93.72 Million ≈ $13.71 Million |
0.087x | -17.40% |
| 2019-12-31 | CN¥1.02 Billion ≈ $148.79 Million |
CN¥107.53 Million ≈ $15.73 Million |
0.106x | +65.34% |
| 2018-12-31 | CN¥979.31 Million ≈ $143.30 Million |
CN¥62.64 Million ≈ $9.17 Million |
0.064x | +33.81% |
| 2017-12-31 | CN¥912.11 Million ≈ $133.47 Million |
CN¥43.60 Million ≈ $6.38 Million |
0.048x | -65.16% |
| 2016-12-31 | CN¥522.81 Million ≈ $76.50 Million |
CN¥71.72 Million ≈ $10.49 Million |
0.137x | +120.22% |
| 2015-12-31 | CN¥457.58 Million ≈ $66.96 Million |
CN¥28.50 Million ≈ $4.17 Million |
0.062x | +8.38% |
| 2014-12-31 | CN¥395.37 Million ≈ $57.86 Million |
CN¥22.72 Million ≈ $3.33 Million |
0.057x | -51.42% |
| 2013-12-31 | CN¥332.63 Million ≈ $48.67 Million |
CN¥39.35 Million ≈ $5.76 Million |
0.118x | +54.43% |
| 2012-12-31 | CN¥210.43 Million ≈ $30.79 Million |
CN¥16.12 Million ≈ $2.36 Million |
0.077x | -- |
About Shaanxi Kanghui Pharm Co Ltd
Shaanxi Kanghui Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical intermediates in China. It is involved in the research, development, production, and sale of traditional Chinese medicine preparations; research and development of prepared slices of Chinese medicinal herbs and pharmaceutical intermediates; and pharmaceutical distribution of biolo… Read more